Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan, Shire Battle In Dry Eye As Generics Advance

Executive Summary

Market Snapshot: Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending arrival of a generic Restasis throws a curveball into the whole category.

Advertisement

Related Content

Allergan Fights Generic Headwinds, Activist Investors
Oyster Point Looks To Compete In Dry Eye With Nasal Spray Therapeutic
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Shire Touts Ongoing Xiidra Growth, Targets Increased Medicare Access
Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents
Allergan Shifts Restasis Patents To Native American Tribe To Invoke Immunity From IPR
Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis
Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma
Shire's Xiidra Gets Advantageous Label Covering Signs, Symptoms Of Dry Eye Disease

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100019

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel